Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)

Email this Article

Send with mail | ahoo instead.
Required Needs to be a valid email
Required Needs to be a valid email
Instead of Chasing Every New Vaccine "Breakthrough," Trade the Whole Sector
https://moneymorning.com/?p=1170808
Required Please enter the correct value.
Twitter
Stocks: LLY, XBI

Instead of Chasing Every New Vaccine "Breakthrough," Trade the Whole Sector

By Andrew Keene, Special Contributor, Money Morning • October 31, 2020

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

As the pandemic continues to rage on, so does the race to develop a vaccine. But not every biotech company is doing well in the search for an effective vaccine or treatment.

Since day one, companies came out of the woodwork to throw their hat into the ring - hoping to be the first to develop the coveted medical breakthrough. Many of these firms, however, have had their fair share of struggles.

One of the latest companies to face some tough hurdles is U.S. pharmaceutical company Eli Lilly and Co. (NYSE: LLY). Since the beginning of the pandemic, Eli Lilly has been a frontrunner in this race, searching for authorization for its antibody treatment.

But the company has yet to find solid ground to stand on.

Eli Lilly has not only struggled to find a vaccine, but it also fell short of analysts' expectations for third-quarter profits. And this was all thanks to the increased costs to develop possible COVID-19 therapies. But the drop in revenue isn't the only thing putting the stock in a bad light.

Earlier this month, the Eli Lilly antibody clinical trial was paused due to safety concerns. And a day before the earnings announcement, it was announced that no additional COVID-19 patients that had been hospitalized would receive its treatment. This decision was made after data from a government-run trial revealed that the therapy was failing and was unlikely to help patients recover as the company has hoped.

And if I'm honest, I wasn't all that surprised by this bad news surrounding Eli Lilly. So today I'm going to show you a much more profitable move to make instead of chasing every vaccine "breakthrough" news...

Until There's a Breakthrough, Bet on This Move

I find it interesting that so many investors chase companies that make noise about a possible vaccine because that's what most of it is - noise.

It's equally interesting that despite months and months without a vaccine, investors are still running after those same stocks, pushing the stock higher with any whispering of a "breakthrough."

The reason why I find it so interesting is that it's pretty well-known that pharmaceutical companies don't make much money on vaccines or drugs. LLY has spent nearly $400 million pursuing this vaccine and hasn't been left with much but a downturned stock and revenue loss. Not a good look for this company or its investors.

And that's precisely why I've stayed away from pouring money into vaccine dream-chasers.

But there is a way - a smart, profitable way - to invest in the race to the vaccine. It's just not the move you might think to make. And that move is the SPDR S&P Biotech ETF (NYSEArca: XBI), which tracks the biotech sector.

The way to play it? Look to short this ETF on any rally - and then take your money and run.

And before you go, make sure you check out this must-watch stock-picking presentation...

You see, I hate watching people try to chase money by following the news headlines - because there's so much information they leave out.

Do you know who else hates this? My colleague, three-decade trading expert Shah Gilani, who also happens to be Money Morning's Chief Investment Strategist. And recently he held his first-ever stock-picking lightning round event.

During this event, he'll be flying through stocks - over 50, to be exact - telling you which to consider buying NOW and which not to touch with a 10-foot pole.

This could be the largest buying opportunity in stock market history... click here now.

Follow Money Morning on Facebook and Twitter.

Join the conversation. Click here to jump to comments…

Andrew KeeneAndrew Keene

About the Author

Browse Andrew's articles | View Andrew's research services

Andrew Keene is a globally known trader and a renowned expert on all things options.

… Read full bio

Login
guest
guest
0 Comments
Inline Feedbacks
View all comments
LIVE
Visit Money Morning Live


Latest News

January 19, 2023 • By Money Morning Stock Research Team

These Stocks Could Go To $0

January 9, 2023 • By Money Morning Stock Research Team

The Government Is Pouring $391 Billion Into These Stocks - Buy Now

December 27, 2022 • By Money Morning Staff Reports

6 IPOs in 2023 You Can’t Afford to Miss
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover This Is VWAP Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Warlock's World Penny Nation Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Vega Burst Trader Flashpoint Trader Darknet Hyper Momentum Trader

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell My Info

wpDiscuz